Getting It Right Early: The Role of Rapid Syndromic Testing in Managing Severe Infections
Date: 19 August 2023, Saturday
Time: 15:00 – 15:45
Antimicrobial resistance (AMR) is an important issue in intensive care units (ICUs). AMR makes “getting antibiotic therapy right early” much more difficult. Rapid syndromic testing is the use of targeted diagnostics to detect the causative organism and their antimicrobial susceptibility pattern for pneumonia, bloodstream infections and other important infection types. This can allow the early antibiotic choice to be the “right” choice, and therefore may improve patient outcomes.
Following the rise of extended-spectrum beta-lactamases (ESBLs), and the establishment of carbapenems as treatment of choice for serious infections with ESBL producers, carbapenem resistance is now an unfortunate part of modern healthcare. For Enterobacterales, carbapenem resistance is typically mediated by carbapenemases. These include Class A enzymes (most notably KPC), Class B enzymes (for example, NDM, IMP and VIM) and Class D enzymes (such as OXA-48 and related enzymes). Knowledge of the specific type of carbapenemase is important for therapy and infection control reasons in the ICU. From the therapeutic viewpoint, new antibiotics have quite a diversity in their spectrum of activity against carbapenemase producers. It is only with early and specific detection of AMR genes that use of new antibiotics can be optimised.
1. To learn the advantages of rapid syndromic testing in detecting antimicrobial resistance (AMR) and optimizing early antibiotic therapy.
2. To describe the clinical impact of rapid syndromic testing in ICU setting.
Professor David Paterson, Singapore
Professor Paterson directs ADVANCE-ID (ADVANcing Clinical Evidence for Infectious Diseases) at Saw Swee Hock School of Public Health. ADVANCE-ID is a clinical trials network comprising more than 40 hospitals across Asia. This network is jointly funded by the Wellcome Trust and a number of Singaporean institutions with an aim to conduct clinically important trials in the field of antimicrobial resistance (AMR). This comprises trials of antibiotics, diagnostics and prevention strategies. He is also an Honorary Professor at the University of Queensland and has more than 500 peer-reviewed publications predominantly in the area of AMR. His research focuses on the molecular and clinical epidemiology of infections with antibiotic-resistant organisms, with the intent of translating knowledge into optimal prevention and treatment of these infections. Multi-country clinical trials are the major component of his research portfolio, and the predominant focus of ADVANCE-ID.
Reducing the gap with rapid molecular diagnostics of direct pathogen detection and making a difference for better care
Date: 19 August 2023
Time: 3:00 – 3.45 p.m.
This symposium session will focus on respiratory syndromic diagnostics using the QIAstat-Dx system, as well as a new QIAstat-Dx blood culture identification panel for the study of antimicrobial resistance in bloodstream infections. Join us to discover how fast, highly sensitive and specific detection of pathogens has the potential to improve patient management and make a difference in patient outcomes.
1. Updates on how rapid molecular diagnostics are changing the post-pandemic infectious diseases landscape.
2. Outline the clinical utility and significance of rapid molecular testing towards patient treatment, infection control and healthcare costs.
3. Introduction to the new QIAstat-Dx BCID GN Plus AMR Panel with AMR gene targets for research.
4. The utilization of BCID and AMR gene targets and how it will impact conventional testing methods.
Dr. Wong Jin Shyan, Malaysia
Internal Medicine Consultant, Borneo Medical Centre Sarawak